Skip to main content
main-content
Top

19-06-2020 | FDA | News

approvalsWatch

Pembrolizumab approved for advanced TMB-H solid tumors

Author:
Lynda Williams

medwireNews: Pembrolizumab has been given accelerated approval by the US FDA for the treatment of unresectable or metastatic solid malignancies with a high tumor mutational burden (TMB-H).

The PD-1 inhibitor may be given to adult and pediatric patients who have progressed after initial therapy, have no further treatment options, and show a TMB of 10 mutations/Mb or higher on the simultaneously approved companion diagnostic test. 

However, the prescribing information has a “Limitation of Use” reminding physicians that “the safety and effectiveness of pembrolizumab in pediatric patients with TMB-H central nervous system cancers have not been established.”

This latest pembrolizumab approval follows the earlier tumor-agnostic approval for use in solid tumors that are microsatellite instability-high or have mismatch repair deficiency.

The decision is based on a retrospective analysis of data from the multi-tumor KEYNOTE-158 trial, where 29% of 102 TMB-H patients achieved an objective response, with 57% of responses ongoing at 1 year. Data from other cohorts of the study led to pembrolizumab approval for patients with metastatic small-cell lung cancer and those with advanced cervical cancer or primary mediastinal large B-cell lymphoma.

The recommended dose of pembrolizumab for TMB-H adult patients is 200 mg every 3 weeks or 400 mg every 6 weeks until unacceptable toxicity or disease progression, and 2 mg/kg to a maximum of 200 mg every 3 weeks for children.

The most common adverse events (AEs) associated with pembrolizumab include fatigue, musculoskeletal pain, and gastrointestinal side effects, as well as immune-mediated AEs of pneumonitis, colitis, hepatitis, endocrinopathy, nephritis, and skin reactions.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

Related topics

Enriched treatment pathway for non-driver NSCLC

What is it and why do I need it?

Have your say on Medicine Matters

Visit the conference hub

Image Credits